LEXINGTON, Mass., March 23,
2022 /PRNewswire/ --
LogicBio® Therapeutics, Inc. (Nasdaq:
LOGC), a clinical-stage genetic medicine company, today announced
that president and chief executive officer, Frederic Chereau, will present a company
overview at the H.C. Wainwright Gene Therapy and Gene Editing
Conference. The presentation will be available on demand beginning
at 7:00 a.m. ET on March 30, 2022.
A webcast of the presentation will be made available on the
Investors section of the Company's website at
https://investor.logicbio.com. The webcast replay will be available
for approximately 30 days.
About LogicBio®
Therapeutics
LogicBio Therapeutics is a clinical-stage genetic medicine
company pioneering genome editing and gene delivery platforms to
address rare and serious diseases from infancy through adulthood.
The company's genome editing platform, GeneRide™, is a new approach
to precise gene insertion harnessing a cell's natural DNA repair
process potentially leading to durable therapeutic protein
expression levels. The company's gene delivery platform, sAAVy™, is
an adeno-associated virus (AAV) capsid engineering platform
designed to optimize gene delivery for treatments in a broad range
of indications and tissues. The company is based in Lexington, MA. For more information, visit
www.logicbio.com, which does not form a part of this release.
Investor Contacts:
Stephen Jasper
Gilmartin Group
858-525-2047
stephen@gilmartinir.com
Media Contacts:
Adam
Daley
Berry & Company Public Relations
W:212-253-8881
C: 614-580-2048
adaley@berrypr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-hc-wainwright-gene-therapy-and-gene-editing-conference-301509368.html
SOURCE LogicBio Therapeutics